|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.455 USD | -1.18% |
|
+6.75% | -24.34% |
| 12-08 | Weight-loss drug developers line up to tap lucrative market as competition heats up | RE |
| 12-01 | Altimmune, Inc. Announces CEO Changes | CI |
Company Valuation: Altimmune, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 417 | 363.1 | 808.4 | 604.4 | 512.8 | 576 | - | - |
| Change | - | -12.92% | 122.62% | -25.23% | -15.16% | 12.32% | - | - |
| Enterprise Value (EV) 1 | 417 | 363.1 | 697.3 | 469.3 | 380.9 | 519.8 | 508.2 | 343.3 |
| Change | - | -12.92% | 92.02% | -32.7% | -18.84% | 36.48% | -2.24% | -32.44% |
| P/E ratio | -5.91x | -3.9x | -9.09x | -6.78x | -5.38x | -5.6x | -4.26x | -5.21x |
| PBR | - | - | - | - | 4.22x | - | - | - |
| PEG | - | -0.2x | 0.4x | 0.82x | 0.3x | 0.2x | -0.1x | 0.3x |
| Capitalization / Revenue | 50.9x | 82.3x | -11,889x | 1,419x | 25,640x | 148,064x | 230,388x | 27.8x |
| EV / Revenue | 50.9x | 82.3x | -10,255x | 1,102x | 19,044x | 133,629x | 203,269x | 16.6x |
| EV / EBITDA | - | -3.77x | -7.93x | -4.92x | -3.7x | -5.78x | -4.29x | -2.56x |
| EV / EBIT | -7.61x | -4.25x | -7.95x | -5.62x | -3.69x | -5.76x | -4.04x | -2.64x |
| EV / FCF | -12x | -4.02x | -11.1x | -6.19x | -4.77x | -7.86x | -4.7x | -1.97x |
| FCF Yield | -8.31% | -24.9% | -8.99% | -16.2% | -21% | -12.7% | -21.3% | -50.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.91 | -2.35 | -1.81 | -1.66 | -1.34 | -0.9857 | -1.296 | -1.06 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8.185 | 4.41 | -0.068 | 0.426 | 0.02 | 0.00389 | 0.0025 | 20.71 |
| EBITDA 1 | - | -96.36 | -87.94 | -95.45 | -102.9 | -89.94 | -118.5 | -134 |
| EBIT 1 | -54.8 | -85.54 | -87.74 | -83.51 | -103.2 | -90.23 | -125.8 | -130 |
| Net income 1 | -49.04 | -97.09 | -84.71 | -88.45 | -95.06 | -84.45 | -122.6 | -123.7 |
| Net Debt 1 | - | - | -111.1 | -135.2 | -131.9 | -56.16 | -67.8 | -232.6 |
| Reference price 2 | 11.280 | 9.160 | 16.450 | 11.250 | 7.210 | 5.520 | 5.520 | 5.520 |
| Nbr of stocks (in thousands) | 36,968 | 39,644 | 49,146 | 53,729 | 71,125 | 104,342 | - | - |
| Announcement Date | 2/25/21 | 3/15/22 | 2/28/23 | 3/27/24 | 2/27/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.6x | 133628.53x | -5.78x | - | 576M | |
| 49.75x | 12.14x | 43.64x | -.--% | 54.73B | |
| -31.5x | 79.91x | -35.32x | -.--% | 41.41B | |
| 16.31x | 5.72x | 12.97x | 1.74% | 38.87B | |
| -25.44x | 3.37x | -9.87x | -.--% | 23.05B | |
| 17.18x | 4.22x | 11.22x | -.--% | 19.29B | |
| 28.27x | 5.56x | 15.41x | -.--% | 17.8B | |
| -493.4x | 28.5x | 672.01x | -.--% | 14.13B | |
| -13.21x | 165.76x | -25.85x | -.--% | 13.12B | |
| -182.69x | 44.91x | -179.17x | -.--% | 12.78B | |
| Average | -64.03x | 13,397.86x | 49.93x | 0.19% | 23.58B | |
| Weighted average by Cap. | -30.47x | 358.69x | 36.30x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- ALT Stock
- Valuation Altimmune, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition